Evidence map›Paper›PMID 36919944›Full record

ArticleJournal of diabetes investigation2023

Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.

Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06533527 (Randomized Trial of Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy), which is not on this map. Cited by 57 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 6 pooled it
26.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06533527 phase4completedstarted 2024, after this paper: background citation

Randomized Trial of Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

Ran2024Enrolled69Registered outcomes3Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Gastroparesis, ObesityArmsGLP-1 medication
PMID 36870274other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 6 syntheses or guidelines pooled it, 129 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Review
  8. Observational
  9. Article
  10. Glucagon-like peptide-1 receptor agonists and periprocedural pulmonary aspiration: where are we now?Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Toshiko KoboriDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Yukiko OnishiDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1180-5982
Yoko YoshidaDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Tazu TaharaDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Takako KikuchiDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Tetsuya KubotaDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0341-3137
Masahiko IwamotoDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Tomonobu SawadaDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Reo KobayashiDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Hiroaki FujiwaraDivision of Gastroenterology, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
Masato KasugaDivision of Diabetes and Metabolism, The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo, Japan.
The Institute of Medical Science, Asahi Life Foundation · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS/

introductionPrevious studies have reported that the glucagon-like peptide-1 receptor agonist (GLP-1RA) delays gastric emptying, and gastric emptying was assessed by the MATERIALS AND

methodsThis study was a matched pair case-control study. The study population consisted of 1,128 individuals with diabetes who had esophagogastroduodenoscopy at our clinic between July 2020 and June 2022. To account for differences in characteristics, such as age, sex, insulin treatment and glycated hemoglobin, we carried out a one-to-one nearest neighbor propensity score matching analysis between diabetes patients with and without GLP-1RA treatment. After matching, we compared the presence of gastric residue in an esophagogastroduodenoscopy by the McNemar test between patients with and without GLP-1RA treatment.

resultsAfter the propensity score matching, we selected 205 pairs. In the propensity score-matched comparison, the proportion of gastric residue was statistically significantly higher in the GLP-1RA treatment group (0.49% vs 5.4%, P = 0.004). The details of GLP-1RA prescribed for the 11 patients with gastric residue were liraglutide once daily 1.8 mg (n = 2), dulaglutide once weekly 0.75 mg (n = 5), semaglutide once weekly 0.5 mg (n = 2) and semaglutide once weekly 1.0 mg (n = 2).

conclusionGLP-1RA treatment is associated with gastric residue in an esophagogastroduodenoscopy in patients with diabetes.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsCase-Control StudiesGlucagon-Like Peptide-1 Receptor AgonistsHumansLiraglutideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutideEsophagogastroduodenoscopyGastric residueGlucagon-like peptide-1 receptor agonist treatment

Identifiers

PMID36919944
PMCPMC10204182
OpenAlexW4324311440

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.